Antisense oligonucleotide: A promising therapeutic option to beat COVID-19

被引：13
作者：
Quemener, Anais M. [1 ]
Galibert, Marie-Dominique [1 ,2 ]
机构：
[1] Univ Rennes, IGDR Inst Genet & Dev Rennes, CNRS, UMR 6290, Rennes, France
[2] Univ Hosp Rennes, Dept Mol Genet & Genom, CHU Rennes, Rennes, France
来源：
WILEY INTERDISCIPLINARY REVIEWS-RNA | 2022年 / 13卷 / 04期
关键词：
antisense oligonucleotide; ASO; SARS-CoV-2; therapeutic option; MESSENGER-RNA VACCINES; INHIBITION; SARS-COV-2; NUSINERSEN; FOMIVIRSEN; THERAPIES; VARIANT; DRUG; MICE;
D O I：
10.1002/wrna.1703
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The COVID-19 crisis and the development of the first approved mRNA vaccine have highlighted the power of RNA-based therapeutic strategies for the development of new medicines. Aside from RNA-vaccines, antisense oligonucleotides (ASOs) represent a new and very promising class of RNA-targeted therapy. Few drugs have already received approval from the Food and Drug Administration. Here, we underscored why and how ASOs hold the potential to change the therapeutic landscape to beat SARS-CoV-2 viral infections. This article is categorized under: RNA Interactions with Proteins and Other Molecules > Small Molecule-RNA Interactions
引用
收藏
页数：12
相关论文
共 52 条
  • [1] Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
    Akdim, Fatima
    Tribble, Diane L.
    Flaim, JoAnn D.
    Yu, Rosie
    Su, John
    Geary, Richard S.
    Baker, Brenda F.
    Fuhr, Rainard
    Wedel, Mark K.
    Kastelein, John J. P.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 (21) : 2650 - 2659
  • [2] [Anonymous], 2023, Neurology, V100, P936, DOI 10.1212/WNL.0000000000012406
  • [3] ANONYMOUS, 2019, AUST PRESCR, V42, P75, DOI DOI 10.18773/AUSTPRESCR.2019.019
  • [4] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
  • [5] Belfort R, 2002, AM J OPHTHALMOL, V133, P467
  • [6] Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein
    Belouzard, Sandrine
    Millet, Jean K.
    Licitra, Beth N.
    Whittaker, Gary R.
    [J]. VIRUSES-BASEL, 2012, 4 (06): : 1011 - 1033
  • [7] FAST-SPREADING COVID VARIANT CAN ELUDE IMMUNE RESPONSES
    Callaway, Ewen
    [J]. NATURE, 2021, 589 (7843) : 500 - 501
  • [8] COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
    Chung, Young Hun
    Beiss, Veronique
    Fiering, Steven N.
    Steinmetz, Nicole F.
    [J]. ACS NANO, 2020, 14 (10) : 12522 - 12537
  • [9] Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]
  • [10] Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
    Corey, David R.
    [J]. NATURE NEUROSCIENCE, 2017, 20 (04) : 497 - 499
123456